After a disastrous first half of the year, at least three biopharma hedge funds finished 2022 in the black, while another came close to being profitable.
For most of these firms — which rarely make significant changes to their top holdings from quarter to quarter — it was simply a case of watching their favorite stocks recover after a long string of losses.
